Literature DB >> 8990432

Prevention practices for perinatal group B streptococcal disease: a multi-state surveillance analysis. Neonatal Group B Streptococcal Disease Study Group.

C G Whitney1, B D Plikaytis, W S Gozansky, J D Wenger, A Schuchat.   

Abstract

OBJECTIVE: To evaluate hospital-based practices for perinatal group B streptococcal disease prevention and to identify institutional factors related to the disease.
METHODS: We surveyed microbiology laboratories and obstetric programs during 1994 at hospitals in five states with active surveillance for invasive group B streptococcal disease. Institutions provided information on methods for detecting carriers and on obstetric policies for group B streptococcal disease prevention. We used linear regression to identify prevention practices and hospital characteristics that correlated with the number of cases of early-onset disease.
RESULTS: Of 295 hospitals, 247 (84%) laboratories and 154 (52%) obstetric programs completed the survey. Most (83%) laboratories performed group B streptococcal cultures on rectal and vaginal specimens, but only 12 (6%) used selective broth media. Among the obstetric programs, 54 (35%) had policies on some aspect of group B streptococcal disease prevention. Of the hospitals with policies, 21 (48%) recommended intrapartum antimicrobial prophylaxis for women with risk factors outlined by the 1992 ACOG statement. Adjusting for the number of births, there were more cases of early-onset group B streptococcal disease in institutions providing care for more African American women and for more women with no prenatal care. Institutions that had group B streptococcal screening policies had fewer early-onset cases.
CONCLUSIONS: Many institutions with prevention policies followed practices that differed from those recommended in published prevention statements. Having any screening policy, however, was associated with reduced early-onset disease, independent of the risk profile of the patient population. Adopting prevention policies is most urgent for practices serving individuals at increased risk, such as African American women and women without prenatal care.

Entities:  

Mesh:

Year:  1997        PMID: 8990432     DOI: 10.1016/s0029-7844(96)00372-9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Temporal characterization of carrot broth-enhanced real-time PCR as an alternative means for rapid detection of Streptococcus agalactiae from prenatal anorectal and vaginal screenings.

Authors:  Erik Munson; Maureen Napierala; Kimber L Munson; Anne Culver; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

2.  Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections.

Authors:  Anne Schuchat; Aaron Roome; Elizabeth R Zell; Heather Linardos; Sara Zywicki; Katherine L O'Brien
Journal:  Matern Child Health J       Date:  2002-06

3.  Comparison of carrot broth- and selective Todd-Hewitt broth-enhanced PCR protocols for real-time detection of Streptococcus agalactiae in prenatal vaginal/anorectal specimens.

Authors:  Timothy Block; Erik Munson; Anne Culver; Katharine Vaughan; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

Review 4.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

5.  Liberal diagnosis and treatment of intrauterine infection reduces early-onset neonatal group B streptococcal infection but not sepsis by other pathogens.

Authors:  H Wolf; A H Schaap; B J Smit; L Spanjaard; A H Adriaanse
Journal:  Infect Dis Obstet Gynecol       Date:  2000

6.  Detection of Group B Streptococcus Directly from Collected ESwab Samples by Use of the BD Max GBS Assay.

Authors:  Suzane Silbert; Talita T Rocchetti; Alicia Gostnell; Carly Kubasek; Raymond Widen
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.